Insulet (PODD)
(Delayed Data from NSDQ)
$236.58 USD
-1.10 (-0.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $236.69 +0.11 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.58 USD
-1.10 (-0.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $236.69 +0.11 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Insulet (PODD) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Insulet (PODD) closed at $173.42, indicating a +1.85% shift from the previous trading day.
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet (PODD) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Insulet (PODD) reachead $166.19 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?
by Zacks Equity Research
Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).